Payment overview · 2025
General Payments
$25,121.39
118 reported records · 31 companies
Healthcare provider profile · identity verified
Ashkan Karimi, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · MANASSAS, VA · NPI 1982996716
Verified facts
What the public records show
CMS Open Payments records show Ashkan Karimi, M.D. received $25,121.39 in general payments during 2025 across 118 reported records.
AngioDynamics, Inc. accounted for 60.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 43 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $15,061.51 | 60.0% | 4 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $5,890.63 | 23.4% | 27 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $963.99 | 3.8% | 6 | 2025 |
| Recor Medical Inc | Unresolved — no canonical attribution shown | $690.52 | 2.8% | 10 | 2025 |
| Reflow Medical Inc | Unresolved — no canonical attribution shown | $289.67 | 1.1% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$266.56 | 1.1% | 2 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $165.93 | 0.7% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $153.74 | 0.6% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $153.19 | 0.6% | 7 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $135.05 | 0.5% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $133.04 | 0.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $124.51 | 0.5% | 1 | 2025 |
| Ionis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $122.03 | 0.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $105.36 | 0.4% | 5 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $84.28 | 0.3% | 6 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $82.40 | 0.3% | 4 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $76.94 | 0.3% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $74.74 | 0.3% | 2 | 2025 |
| ConvaTec Inc. | Unresolved — no canonical attribution shown | $69.16 | 0.3% | 2 | 2025 |
| Cook Medical LLC | Unresolved — no canonical attribution shown | $64.26 | 0.3% | 2 | 2025 |
| W. L. Gore & Associates, Inc. | Unresolved — no canonical attribution shown | $64.26 | 0.3% | 2 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $60.27 | 0.2% | 3 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $47.25 | 0.2% | 1 | 2025 |
| Terumo Medical Corporation | Unresolved — no canonical attribution shown | $44.47 | 0.2% | 1 | 2025 |
| BridgeBio Pharma, Inc. | Unresolved — no canonical attribution shown | $41.54 | 0.2% | 2 | 2025 |
| CVRx, Inc. | Unresolved — no canonical attribution shown | $39.24 | 0.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $36.73 | 0.1% | 2 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $24.79 | 0.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.36 | 0.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.00 | 0.1% | 1 | 2025 |
| Urgo Medical North America, LLC | Unresolved — no canonical attribution shown | $14.97 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Long term medical supply or device loan | $15,000.00 | 1 |
| Food and Beverage | $4,877.79 | 114 |
| Consulting Fee | $3,300.00 | 1 |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,500.00 | 1 |
| Travel and Lodging | $443.60 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $15,061.51 | 4 | 2025 |
Source payment records
|
|||||
| SUPERA Normalized: supera |
Device | Abbott Laboratories | $3,361.58 | 2 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $1,948.56 | 12 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $963.99 | 6 | 2025 |
Source payment records
|
|||||
| Paradise Ultrasound Renal Denervation System Normalized: paradise ultrasound renal denervation system |
Device | Recor Medical Inc | $690.52 | 10 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK PERIPHERAL Normalized: diamondback peripheral |
Device | Abbott Laboratories | $448.30 | 8 | 2025 |
Source payment records
|
|||||
| ELLIPSYS VASCULAR ACCESS SYSTEM Normalized: ellipsys vascular access system |
Device | Medtronic, Inc. | $182.56 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $165.93 | 5 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $153.19 | 7 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $133.04 | 2 | 2025 |
Source payment records
|
|||||
| TRYNGOLZA Normalized: tryngolza |
Drug | Ionis Pharmaceuticals, Inc. | $122.03 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $84.28 | 6 | 2025 |
Source payment records
|
|||||
| HAWKONE Normalized: hawkone |
Device | Medtronic, Inc. | $84.00 | 1 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROGLIDE Normalized: perclose proglide |
Device | Abbott Laboratories | $83.55 | 3 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $82.40 | 4 | 2025 |
Source payment records
|
|||||
| AQUACEL AG+ Normalized: aquacel ag |
Device | ConvaTec Inc. | $69.16 | 2 | 2025 |
Source payment records
|
|||||
| GORE VIABAHN VBX Balloon Expandable Endo Normalized: gore viabahn vbx balloon expandable endo |
Device | W. L. Gore & Associates, Inc. | $64.26 | 2 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $60.52 | 3 | 2025 |
Source payment records
|
|||||
| CT THROMBECTOMY SYSTEM KIT Normalized: ct thrombectomy system kit |
Device | Stryker Corporation | $50.03 | 1 | 2025 |
Source payment records
|
|||||
| FLOWTRIEVER CATHETER, S Normalized: flowtriever catheter s |
Device | Stryker Corporation | $50.03 | 1 | 2025 |
Source payment records
|
|||||
| Peripheral Vascular Undivided Normalized: peripheral vascular undivided |
Device | Philips North America LLC | $47.25 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $44.84 | 2 | 2025 |
Source payment records
|
|||||
| ANGIO-SEAL Normalized: angio seal |
Device | Terumo Medical Corporation | $44.47 | 1 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Bard Peripheral Vascular, Inc. | $42.31 | 2 | 2025 |
Source payment records
|
|||||
| Attruby Normalized: attruby |
Drug | BridgeBio Pharma, Inc. | $41.54 | 2 | 2025 |
Source payment records
|
|||||
| ROTAPRO Normalized: rotapro |
Device | Boston Scientific Corporation | $41.28 | 2 | 2025 |
Source payment records
|
|||||
| Barostim Neo System Normalized: barostim neo system |
Device | CVRx, Inc. | $39.24 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $36.73 | 2 | 2025 |
Source payment records
|
|||||
| Varithena Administration Pack Normalized: varithena administration pack |
Device | Boston Scientific Corporation | $34.66 | 1 | 2025 |
Source payment records
|
|||||
| ZILVER PTX Normalized: zilver ptx |
Device | Cook Medical LLC | $34.02 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $33.44 | 1 | 2025 |
Source payment records
|
|||||
| AVVIGO Guidance System Normalized: avvigo guidance system |
Device | Boston Scientific Corporation | $28.00 | 3 | 2025 |
Source payment records
|
|||||
| EMBOSHIELD NAV6 Normalized: emboshield nav6 |
Device | Abbott Laboratories | $26.43 | 1 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $24.79 | 1 | 2025 |
Source payment records
|
|||||
| LIMFLOW SYSTEM Normalized: limflow system |
Device | Stryker Corporation | $24.71 | 1 | 2025 |
Source payment records
|
|||||
| ACCULINK Normalized: acculink |
Device | Abbott Laboratories | $22.21 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| LUTONIX Drug Coated Balloon Normalized: lutonix drug coated balloon |
Device | Bard Peripheral Vascular, Inc. | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| SYNERGY Normalized: synergy |
Device | Boston Scientific Corporation | $16.65 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $15.71 | 1 | 2025 |
Source payment records
|
|||||
| VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP Normalized: vashe wound solution 250 ml 8 5 fl oz flip top cap |
Device | Urgo Medical North America, LLC | $14.97 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $14.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 87 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
87 | 27 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
45 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
87 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 196 | 87 |
| Atorvastatin Calcium | Atorvastatin Calcium | 155 | 53 |
| Metoprolol Succinate | Metoprolol Succinate | 121 | 42 |
| Furosemide | Furosemide | 117 | 48 |
| Carvedilol | Carvedilol | 109 | 41 |
| Eliquis | Apixaban | 87 | 27 |
| Amlodipine Besylate | Amlodipine Besylate | 78 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 78 | 25 |
| Xarelto | Rivaroxaban | 65 | 19 |
| Cilostazol | Cilostazol | 56 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 47 | 17 |
| Entresto | Sacubitril/Valsartan | 45 | 11 |
| Losartan Potassium | Losartan Potassium | 41 | 17 |
| Jardiance | Empagliflozin | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 33 | 14 |
| Metoprolol Tartrate | Metoprolol Tartrate | 30 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 27 | 11 |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Spironolactone | Spironolactone | 18 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | suppressed |
| Repatha Syringe | Evolocumab | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 15 | suppressed |
| Pentoxifylline | Pentoxifylline | 14 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Prednisone | Prednisone | 12 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $25,121.39 · 118 records | AngioDynamics, Inc. | ACCULINK, ANGIO-SEAL, AQUACEL AG+, AURYON LASER SYSTEM 100-120 VAC, AVVIGO Guidance System, Assure WCD, Attruby, Barostim Neo System, CAMZYOS, CAPVAXIVE, CT THROMBECTOMY SYSTEM KIT, DIAMONDBACK PERIPHERAL, ELIQUIS, ELLIPSYS VASCULAR ACCESS SYSTEM, EMBOSHIELD NAV6, ESPRIT, FARXIGA, FLOWTRIEVER CATHETER, S, FUROSCIX, GORE VIABAHN VBX Balloon Expandable Endo, HAWKONE, JARDIANCE, Kerendia, LEQVIO, LIMFLOW SYSTEM, LUTONIX Drug Coated Balloon, LifeVest, PERCLOSE PROGLIDE, Paradise Ultrasound Renal Denervation System, Peripheral Vascular Undivided, REPATHA, ROTAPRO, RotarexS 6 F x 135 cm, SUPERA, SYNERGY, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TRYNGOLZA, VASHE WOUND SOLUTION 250 ML (8.5 FL OZ) FLIP TOP CAP, VERQUVO, VYNDAQEL, Varithena Administration Pack, WATCHMAN Access System, ZILVER PTX | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error